American Assets Inc. Purchases New Stake in Evolus, Inc. $EOLS

American Assets Inc. acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 125,000 shares of the company’s stock, valued at approximately $768,000. Evolus makes up about 0.2% of American Assets Inc.’s holdings, making the stock its 14th biggest holding.

Several other institutional investors and hedge funds have also bought and sold shares of EOLS. Manchester Capital Management LLC bought a new stake in Evolus in the 2nd quarter valued at about $26,000. State of Alaska Department of Revenue purchased a new position in Evolus in the 3rd quarter valued at approximately $26,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Evolus during the 3rd quarter valued at about $62,000. Tower Research Capital LLC TRC increased its position in shares of Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after buying an additional 5,691 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in Evolus by 473.6% in the 3rd quarter. Global Retirement Partners LLC now owns 15,200 shares of the company’s stock valued at $93,000 after purchasing an additional 12,550 shares during the period. 90.69% of the stock is owned by institutional investors.

Analysts Set New Price Targets

EOLS has been the topic of a number of recent analyst reports. Stifel Nicolaus lowered their price objective on Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Mizuho set a $15.00 target price on shares of Evolus in a research note on Wednesday. BTIG Research dropped their target price on shares of Evolus from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Evolus presently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider owned 354,388 shares in the company, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.90% of the company’s stock.

Evolus Trading Up 2.0%

NASDAQ EOLS opened at $4.50 on Friday. The firm has a market cap of $291.69 million, a PE ratio of -4.89 and a beta of 1.11. Evolus, Inc. has a 1-year low of $4.41 and a 1-year high of $17.12. The stock has a 50-day moving average of $6.01 and a 200-day moving average of $6.68.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. As a group, equities research analysts forecast that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.